直肠癌新辅助放化疗临床效果的评估·综述-中国肿瘤临床.PDFVIP

360 中国肿瘤临床2015年第42卷第6期 ChinJClinOncol2015.Vol.42.No.6 综 述 · · 直肠癌新辅助放化疗临床效果的评估 ① ② 高卫峰 综述 李会晨 审校 摘要 直肠癌是常见的恶性肿瘤，直肠癌发病率近年有上升趋势。全直肠系膜切除术（totalmesorectalexcision，TME）是直 肠癌的最主要治疗手段，但局部进展期直肠癌患者术后局部复发率高、保肛率低，新辅助放化疗成为局部晚期直肠癌的优选治疗 手段。直肠癌新辅助治疗后的临床效果是临床医生关注的焦点。直肠癌新辅助治疗效果的预测及评估关系到后续治疗方案的 选择，影响患者的生存期及生活质量。 关键词 直肠癌 新辅助放化疗 临床完全缓解 doi:10.3969/j.issn.1000-8179 Clinical evaluation of rectal cancer after neoadjuvant chemoradio- therapy 1 2 Weifeng GAO , Huichen LI Correspondence to: Huichen LI; E-mail: 1477546933@ 1 2 DepartmentofGeneralSurgery,TianjinHaiheHospital,Tianjin300350,China; DiagnosisandTreatmentCenterforAnorectalDis⁃ eases,TianjinUnionMedicalCenter,NankaiUniversity,Tianjin300120,China Abstract Rectal cancer is a common type of malignant tumor, with increasing incidence over the previous years. Total mesorec- tal excision is the most important treatment for rectal cancer. Advanced rectal cancer presents high local recurrence rate and low sphinc- ter preservation rate. For locally advanced rectal cancer, neoadjuvant chemoradiotherapy is the optimal management strategy. In this re- gard, clinicians have focused on investigating the clinical effects of rectal cancer after neoadjuvant chemoradiotherapy. Prediction and evaluation of rectal cancer after neoadjuvant therapy can be used to determine further necessary treatments, effect on quality of life, and survival time of patients. Keywords: rectal cancer, neoadjuvant chemoradiotherapy, clinical complete response 直肠癌是常见的消化道恶性肿瘤，其治疗以外 为进一步提高保肛率、增强降期效果、减少远处 科TME手术为主，临床Ⅱ、Ⅲ期即进展期直肠癌复发 转移、延长生存期，在新辅助放疗的基础上联合同步 率高、保肛率低，大量研究显示：新辅助放化疗可使 化疗，即新